SCHEMBL7880873

SCHEMBL7880873

CN(C(=N)N)C(=O)c1cc2ccc(Oc3ccc(CN4CCCC4)cc3)cc2[nH]1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 2/20 0.43
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
FLT3 P36888 1/20 0.41
BTK Q06187 2/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
HRH3 Q9Y5N1 6/20 0.39
HRH4 Q9H3N8 1/20 0.37
ROCK2 O75116 1/20 0.37
ROCK1 Q13464 1/20 0.37
MLNR O43193 1/20 0.37
DRD2 P14416 1/20 0.37
DRD3 P35462 1/20 0.37
TLR7 Q9NYK1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7879877 0.99 FLT3 (0.42) RXFP1KMT2AMEN1KDM4EMAPT
SCHEMBL7881140 0.92 RXFP1 (0.45) RXFP1KMT2AMEN1KDM4EFLT3
SCHEMBL7881076 0.91 RXFP1 (0.44) RXFP1KMT2AMEN1KDM4EFLT3
SCHEMBL7881119 0.89 ROCK2 (0.39) RXFP1KMT2AMEN1KDM4EMAPT
SCHEMBL7882017 0.87 FLT3 (0.39) RXFP1KMT2AMEN1KDM4EMAPT
SCHEMBL7881978 0.87 FLT3 (0.40) RXFP1KMT2AMEN1KDM4EFLT3
SCHEMBL7879668 0.86 HRH3 (0.39) KDM4EMAPTHRH3DRD2DRD3
SCHEMBL7877811 0.85 HRH3 (0.41) KDM4EMAPTHRH3
SCHEMBL7873680 0.85 KMT2A (0.42) RXFP1KMT2AMEN1FLT3NPC1
SCHEMBL7873334 0.85 KMT2A (0.50) RXFP1KMT2AMEN1KDM4EFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6248772-B1 HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2001-06-19 US disclosed
US-6169107-B1 USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS SUMITOMO PHARMACEUTICAL CO., LTD. (JP) 2001-01-02 US disclosed
EP-0708091-A2 Indoloylguanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1996-04-24 EP disclosed